Factors Influencing Outcomes and Survival in Anal Cancer.

BACKGROUND

We aim to ascertain prognostic factors in the current management of anal cancer within this study.

METHODS

We reviewed the management and outcomes of anal cancer cases over a seven-year period, inclusive (2016-2023). The primary objectives were to assess the demographic characteristics, clinical presentation, and outcomes of all anal cancer patients within our institution. Kaplan-Meier survival analysis was used to estimate survival differences between cohorts, with statistical significance determined using log-rank testing. Cox proportional hazards regression was utilised to identify prognostic factors. Cox regression hazard ratios were reported along with confidence intervals and -values.

RESULTS

The median follow-up time for the study was 29.8 months. Seventy-five patients with anal cancer were included in this study, with 88% (66/75) being squamous cell carcinoma (SCC) and the majority having regional disease (82.7% (62/75)). The median age at diagnosis was 63.4 years (36-94). There was a female preponderance (57.3% (43/75)). In total, 84% (63/75) underwent definitive chemoradiation (), with 7/63 (11.1%) requiring a salvage abdomino-perineal resection (APR) for residual or recurrent disease. Adverse prognostic indicators include those with T4 disease hazard ratio = 3.81, (95% CI 1.13-12.83, * = 0.04), poorly differentiated tumour disease HR = 3.37, (95% CI 1.13-10.02, * = 0.04), having N2 nodal status HR = 5.03, (95% CI 1.11-22.8, * = 0.04), and having metastatic disease at diagnosis HR = 5.8, (95% CI 1.28-26.42, * = 0.02).

CONCLUSION

Presenting characteristics including stage, nodal, and differentiation status remain key prognostic indicators in those diagnosed with anal malignancy.